Search Result

Results for "

lysine methyltransferase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA Methyltransferase (1) Histone Methyltransferase (30) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (5) Autophagy (3) Chemerin Receptor (1) Cholinesterase (ChE) (1) Cytochrome P450 (1) GLP Receptor (1) Histone Demethylase (2) Phosphatase (1) SARS-CoV (1)
By Research Areas:	Cancer (32) Infection (3) Inflammation/Immunology (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Antibodies

Targets Recommended: Histone Methyltransferase DNA Methyltransferase COMT ICMT METTL3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12335

UNC0379 5+ Cited Publications	Histone Methyltransferase	Inflammation/Immunology Cancer
UNC0379 is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 (KMT5A) with an IC₅₀ of 7.3 μM, K_D value of 18.3 μM. UNC0379 can be used in the research of inflammation and cancers, such as pulmonary fibrosis, ovarian cancer, neuroblastoma .

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer .

HY-18627A

PFI-2 hydrochloride 5+ Cited Publications (R)-PFI-2 hydrochloride	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective *SET domain containing lysine* methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀** value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-12991A

BIX-01338 hydrate	Histone Methyltransferase	Cancer
BIX-01338 hydrate is a histone lysine methyltransferase inhibitor.

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-13980

UNC0642 15+ Cited Publications	Histone Methyltransferase	Cancer
UNC0642 is a potent and selective lysine methyltransferases G9a and GLP inhibitor, with an IC₅₀ of <2.5 nM for G9a.

HY-155020

Antitumor agent-101	Histone Methyltransferase GLP Receptor	Cancer
Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC₅₀s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .

HY-12335A

UNC0379 TFA	Histone Methyltransferase	Inflammation/Immunology Cancer
UNC0379 TFA is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 (KMT5A) with an IC₅₀ of 7.3 μM, K_D value of 18.3 μM. UNC0379 TFA can be used in the research of inflammation and cancers, such as pulmonary fibrosis, ovarian cancer, neuroblastoma .

HY-18627

PFI-2 (R)-PFI-2	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective *SET domain containing lysine* methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀** value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-19546A

(R)-BAY-598	Histone Methyltransferase	Cancer
(R)-BAY-598 ((R)-4) is a potent inhibitor of protein-lysine methyltransferase SMYD2, with the IC₅₀ of 1.7 μM .

HY-100757

CPUY074020	Histone Methyltransferase	Cancer
CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase G9a, with an IC₅₀ of 2.18 μM. CPUY074020 possesses anti-proliferative activity .

HY-116971

DCG066	Histone Methyltransferase Apoptosis	Cancer
DCG066 is an inhibitor of lysine methyltransferase G9a. DCG066 can bind directly to G9a and inhibit methyltransferase activity in vitro. DCG066 decreases di-methylation levels of histone H3 lysine 9 (H3K9Me2), inhibits cell proliferation and induces cell apoptosis. DCG066 displays low cytotoxicity in leukemia cell lines with high levels of G9a expression, including K562 .

HY-10587A

BIX-01294 hydrochloride hydrate	Histone Methyltransferase Apoptosis Autophagy	Cancer
BIX-01294 hydrochloride hydrate is a histone-lysine methyltransferase (HMTase) inhibitor, which selective inhibits the G9aHMTase with IC₅₀ of 1.7 μM, reduces histone-3 lysine (9) methylation (H3K9me), induces autophagy and apoptosis in human glioma cells .

HY-100625

BVT948 2 Publications Verification	Phosphatase Cytochrome P450 Histone Methyltransferase	Cancer
BVT948 is a protein tyrosine phosphatase (PTP) inhibitor which can also inhibit several cytochrome P450 (P450) isoforms and lysine methyltransferase SETD8 (KMT5A).

HY-112080A

(R)-BAY-6035	Others	Others
(R)-BAY-6035 is a novel inhibitor that selectively targets the methylation of MAP3K2 by SMYD3, demonstrating nanomolar potency and specificity against kinases and other protein lysine methyltransferases.

HY-135128

Dot1L-IN-5 1 Publications Verification	Histone Methyltransferase	Cancer
Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC₅₀ of 0.17 nM .

HY-135129

Dot1L-IN-6	Histone Methyltransferase	Cancer
Dot1L-IN-6 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.19 nM .

HY-135127

Dot1L-IN-4	Histone Methyltransferase	Cancer
Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.11 nM .

HY-100846

JQEZ5 3 Publications Verification	Histone Methyltransferase	Cancer
JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitively inhibits polycomb repressive complex 2 (PRC2) with an IC₅₀ of 80 nM. JQEZ5 has anti-tumor effects .

HY-113786

EZH2-IN-21	Histone Methyltransferase	Cancer
EZH2-IN-21 is a potent inhibitor of the histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) with anticancer activity. EZH2-IN-21 is competitive with the cofactor SAM and noncompetitive with peptide or nucleosome substrates .

HY-156455

SETD7-IN-1	Histone Methyltransferase	Cancer
SETD7-IN-1 (compound 7) is a PFI-2 (HY-18627) analogue. SETD7-IN-1 is a substrate and inhibitor of *histone lysine* methyltransferase SETD7, with an IC₅₀** of 0.96 ± 0.10 µM .

HY-116605

GSK926	Histone Methyltransferase	Cancer
GSK926 (compound 3) is a selective histone lysine methyltransferase EZH2 inhibitor (IC₅₀=0.02 μM; K_i=7.9 nM), with SAM-competitive and cell-active properties. GSK926 can be used in cancer research .

HY-19313

LLY-507 5+ Cited Publications	Histone Methyltransferase	Cancer
LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase SMYD2. LLY-507 potently inhibits the ability of SMYD2 to methylate p53 peptide with an IC₅₀ <15 nM. LLY-507 serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes .

HY-110196

(S)-PFI-2 hydrochloride	Others	Others
(S)-PFI-2 hydrochloride is an inhibitor of lysine methyltransferase SETD7 and is approximately 500-fold more active than its enantiomer (R)-PFI-2. (R)-PFI-2 is a cofactor-dependent and substrate-competitive inhibitor. (R)-PFI-2 can occupy the substrate peptide binding groove of SETD7 (including the catalytic lysine binding channel) and interact with the cofactor The donor methyl group is in direct contact. However, (S)-PFI-2 was not observed to have the same interaction as (R)-PFI-2 .

HY-111544

EML741	Histone Methyltransferase	Cancer
EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC₅₀ of 23 nM, K_d of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC₅₀, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated .

HY-125244

LEM-14-1189	Histone Methyltransferase	Cancer
LEM-14-1189, a LEM-14 (HY-114340) derivative, is a NSDs inhibitor with IC₅₀s of 418 μM (NSD1), 111 μM (NSD2), and 60 μM (NSD3), respectively. The NSDs, *histone lysine* methyltransferases (HMTases)**, are oncoproteins, drivers of a number of tumors. LEM-14-1189 can be used for multiple myeloma (MM) research .

HY-156285

ZZM-1220	Histone Methyltransferase Apoptosis	Cancer
ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC₅₀s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase .

HY-150680

SARS-CoV-2 nsp14-IN-1	SARS-CoV Histone Methyltransferase DNA Methyltransferase	Infection
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC₅₀ value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases .

HY-16705

BRD4770 3 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a *histone methyltransferase* G9a** inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-10587

BIX-01294 Maximum Cited Publications 22 Publications Verification	Histone Methyltransferase Autophagy	Cancer
BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .

HY-108239

BIX-01294 trihydrochloride	Histone Methyltransferase Autophagy	Cancer
BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .

HY-P10463

ssK36	Histone Methyltransferase	Cancer
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. It is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

HY-138097

α-NETA 5+ Cited Publications	Chemerin Receptor Aldehyde Dehydrogenase (ALDH) Cholinesterase (ChE) Apoptosis	Cancer
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC₅₀ of 9 μM. α-NETA is a potent ALDH1A1 (IC₅₀=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC₅₀=84 µM) and acetylcholinesterase (AChE; IC₅₀=300 µM). α-NETA has anti-cancer activity .

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively .

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	670 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 670 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

670 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 670 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.	Product Name	Target	Research Area

HY-P10463

ssK36	Histone Methyltransferase	Cancer
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. It is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

Species:	Human (12)
Tag:	His (8) Tag Free (3) Strep (1) Myc (1) GST (3) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (3) P. pastoris (1) E. coli (9)

Cat. No.	Compare	Product Name	Species	Source

HY-P76079

	SMYD2 Protein, Human (sf9, His) N-lysine methyltransferase SMYD2; HSKM-B; lysine N-methyltransferase 3C; SMYD2; KMT3C	Human	Sf9 insect cells
	The SMYD2 protein is a multifunctional methyltransferase that can modify histones and non-histone proteins, including p53/TP53 and RB1. Notably, it trimethylates H3 at "Lys-4" (H3K4me3), which is critical for gene activation. SMYD2 Protein, Human (sf9, His) is the recombinant human-derived SMYD2 protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P77376

	HEMK2 Protein, Human (His) methyltransferase N6AMT1; lysine N-methyltransferase 9; N6AMT1; C21orf127; HEMK2; KMT9; PRED28	Human	E. coli
	Contrary to the expected interaction, HEMK2 protein did not bind to TRMT112. This unique feature distinguishes HEMK2 from expected protein-protein interactions typically associated with its functional counterparts. HEMK2 Protein, Human (His) is the recombinant human-derived HEMK2 protein, expressed by E. coli , with C-His labeled tag.

HY-P76080

	SMYD3 Protein, Human (sf9, GST) Histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	Sf9 insect cells
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. SMYD3 Protein, Human (sf9, GST) is the recombinant human-derived SMYD3 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of SMYD3 Protein, Human (sf9, GST) is 335 a.a., with molecular weight of ~58 kDa.

HY-P701940

	aKMT Protein, Sulfolobus islandicus Protein-lysine N-methyltransferase; Archaeal protein lysine methyltransferase; aKMT	Others	E. coli
	Lysine methyltransferase (aKMT) is responsible for catalyzing the methylation of lysine residues in target proteins, using S-adenosyl-L-methionine (SAM) as a methyl donor. The enzyme exhibits broad substrate specificity, showing methylation primarily at "Lys-11", "Lys-16" and "Lys-31" of the vault chromatin protein Cren7 as well as several recombinant Sulfolobus proteins in vitro Ability. aKMT Protein, Sulfolobus islandicus is the recombinant aKMT protein, expressed by E. coli , with tag free. The total length of aKMT Protein, Sulfolobus islandicus is 160 a.a., .

HY-P701941

	aKMT Protein, Sulfolobus islandicus (His, Strep) Protein-lysine N-methyltransferase; Archaeal protein lysine methyltransferase; aKMT	Others	E. coli
	Lysine methyltransferase (aKMT) is responsible for catalyzing the methylation of lysine residues in target proteins, using S-adenosyl-L-methionine (SAM) as a methyl donor. The enzyme exhibits broad substrate specificity, showing methylation primarily at "Lys-11", "Lys-16" and "Lys-31" of the vault chromatin protein Cren7 as well as several recombinant Sulfolobus proteins in vitro Ability. aKMT Protein, Sulfolobus islandicus (His, Strep) is the recombinant aKMT protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of aKMT Protein, Sulfolobus islandicus (His, Strep) is 160 a.a., .

HY-P700258

	*Histone-lysine* N-methyltransferase SMYD3(SMYD3) Protein, Human (His-Myc)**	Human	E. coli
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc) is the recombinant human-derived Histone-lysine N-methyltransferase SMYD3(SMYD3) protein, expressed by E. coli , with N-10*His, C-Myc labeled tag. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc), has molecular weight of 56.5 kDa.

HY-P702618

	EZH2 Protein, Human (P.pastoris, His) ENX-1; Enhancer of zeste homolog 2; lysine N-methyltransferase 6	Human	P. pastoris
	The EZH2 protein is a member of the Polycomb group (PcG). EZH2 Protein, Human (P.pastoris, His) is the recombinant human-derived EZH2, expressed by P. pastoris , with C-6*His labeled tag. The total length of EZH2 Protein, Human (P.pastoris, His) is 746 a.a.,

HY-P701589

	KMT2D Protein, Human KMT2D; Histone-lysine N-methyltransferase 2D; lysine N-methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free. The total length of KMT2D Protein, Human is 155 a.a., .

HY-P701590

	KMT2D Protein, Human (GST) KMT2D; Histone-lysine N-methyltransferase 2D; lysine N-methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag. The total length of KMT2D Protein, Human (GST) is 155 a.a., .

HY-P703071

	SETDB1 Protein, Human (sf9, GST) KMT1E; Histone-lysine N-methyltransferase SETDB1; ERG-associated protein with SET domain (ESET); Histone H3-K9 methyltransferase 4 (H3-K9-HMTase 4); lysine N-methyltransferase 1E; SET domain bifurcated 1; SETDB1; ESET	Human	Sf9 insect cells
	SETDB1 Protein, Human (sf9, GST) is the recombinant human-derived SETDB1, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P77218

	SUV420H2 Protein, Human (His) Histone-lysine N-methyltransferase KMT5C; KMT5C; PP7130	Human	E. coli
	SUV420H2 protein is a histone methyltransferase that methylates H4K20 to generate H4K20me3 and H4K20me2, which are critical for transcriptional regulation and genome integrity. SUV420H2 functions in pericentric heterochromatin, establishes constitutive heterochromatin, and interacts with RB1 family proteins. SUV420H2 Protein, Human (His) is the recombinant human-derived SUV420H2 protein, expressed by E. coli , with N-His labeled tag.

HY-P76081

	SMYD3 Protein, Human (HEK293, His-Flag) Histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	HEK293
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. SMYD3 Protein, Human (HEK293, His-Flag) is the recombinant human-derived SMYD3 protein, expressed by HEK293 , with C-His, C-Flag labeled tag.

HY-P74613

	PR-Set7 Protein, Human N-lysine methyltransferase KMT5A; PR-Set7; KMT5A; PRSET7; SET8; SETD8	Human	E. coli
	The PR-Set7 Protein methylates Lys-20 of histone H4, repressing gene transcription and aiding cell proliferation and chromatin condensation. It is expressed in multiple tissues, including the prostate (RPKM 17.6), esophagus (RPKM 16.8), and others. PR-Set7 Protein, Human is the recombinant human-derived PR-Set7 protein, expressed by E. coli , with tag free.

HY-P76062

	SETD7 Protein, Human (His) Histone-lysine N-methyltransferase SETD7; H3-K4-HMTase SETD7; SET7/9; KIAA1717; KMT7; SET7; SET9	Human	E. coli
	The SETD7 protein is a histone methyltransferase that specifically monomethylates H3K4, a mark associated with transcriptional activation. Its role in gene activation extends to the collagenase and insulin genes, specifically at the insulin promoter when IPF1/PDX-1 is recruited. SETD7 Protein, Human (His) is the recombinant human-derived SETD7 protein, expressed by E. coli , with N-His labeled tag. The total length of SETD7 Protein, Human (His) is 365 a.a., with molecular weight of 47-50 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83151

	SETD7 Antibody (YA2896) Histone H3-K4 methyltransferase SETD7; lysine N-methyltransferase 7; SET domain-containing protein 7; SET7; SET9	WB, IP	Human, Mouse, Rat
	SETD7 Antibody (YA2896) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2896), targeting SETD7, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). SETD7 Antibody (YA2896) can be used for WB, IP experiment in human, mouse, rat background.

HY-P81657

	KMT4 Antibody (YA1402) DOT 1; DOT1L; KMT4; Histone methyltransferase DOT1L; H3 lysine-79 specific	WB, IHC-P	Human, Mouse
	KMT4 Antibody (YA1402) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1402), targeting KMT4, with a predicted molecular weight of 165 kDa (observed band size: 185 kDa). KMT4 Antibody (YA1402) can be used for WB, IHC-P experiment in human, mouse background.

HY-P83329

	NSD3 Antibody (YA3074) Wolf Hirschhorn syndrome candidate 1 like 1; WHSC1L1; NSD3; pp14328; Histone-lysine N-methyltransferase NSD3; Protein whistle	WB, FC	Human, Mouse, Rat
	NSD3 Antibody (YA3074) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3074), targeting NSD3, with a predicted molecular weight of 162 kDa (observed band size: 162 kDa). NSD3 Antibody (YA3074) can be used for WB, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: